Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $93.33 Consensus Target Price from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $93.33.

Several brokerages recently commented on PBH. Wall Street Zen raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 17th. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in PBH. CIBC Private Wealth Group LLC boosted its holdings in shares of Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after purchasing an additional 152 shares during the last quarter. Opal Wealth Advisors LLC purchased a new position in Prestige Consumer Healthcare during the first quarter worth approximately $38,000. Headlands Technologies LLC purchased a new position in Prestige Consumer Healthcare during the fourth quarter worth approximately $40,000. Geneos Wealth Management Inc. boosted its stake in Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after buying an additional 269 shares during the last quarter. Finally, McIlrath & Eck LLC grew its holdings in Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after buying an additional 154 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH traded down $0.15 during trading on Friday, reaching $81.00. 855,797 shares of the company's stock traded hands, compared to its average volume of 303,377. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare has a fifty-two week low of $64.94 and a fifty-two week high of $90.04. The company has a 50-day simple moving average of $84.12 and a 200-day simple moving average of $82.48. The firm has a market cap of $4.00 billion, a PE ratio of 18.88, a P/E/G ratio of 2.45 and a beta of 0.45.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. The company had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. Prestige Consumer Healthcare's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the company earned $1.02 earnings per share. As a group, analysts predict that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.